Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease
Joshua T Dearborn, Keigo Takahashi, Nicholas R Rensing, Michael Wong, Jonathan D Cooper, Mark S Sands · 2026
Read Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease by Joshua T Dearborn, Keigo Takahashi, Nicholas R Rensing, Michael Wong, Jonathan D Cooper, Mark S Sands (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0337880.txt.
Description
Joshua Dearborn and five colleagues test whether cannabidiol, a cannabis compound, can ease seizures in a devastating childhood brain disease, in this 2026 PLOS ONE mouse study. The disease, called CLN2, comes from a broken lysosome gene and brings inflammation, degeneration, and epilepsy. Affected mice received daily cannabidiol from one month of age until the disease's end stage.
Treated mice had their seizures delayed or prevented entirely, compared with mice given only the carrier liquid. Lifespan lengthened slightly, though not by a statistically firm margin. Surprisingly, standard inflammation markers in the brain did not improve, so the anti-seizure benefit seems to work through a different route — a clue for treating epilepsy in this disease.
Catalog record
| CREATOR | Joshua T Dearborn, Keigo Takahashi, Nicholas R Rensing, Michael Wong, Jonathan D Cooper, Mark S Sands |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40563 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |